Sequana, GenPharm International, NemaPharm Inc., University of California deal

SQNA signed a letter of intent to purchase NemaPharm, a developer of drug discovery technologies using the nematode worm, C. elegans, for an undisclosed amount. The worm exhibits similarities to humans at the genetic, molecular and cellular levels, SQNA said. The genomics company plans to use NemaPharm’s technologies to develop animal models of human disease, which will be used to identify therapeutic targets.

Separately, SQNA will develop a mouse transgenics program using technology developed at GenPharm to develop animal models of human genetic diseases. ...